Literature DB >> 28112568

Vitrectomy for Epiretinal Membranes and Macular Holes in Uveitis Patients.

Sara V Branson1, Brendan R McClafferty2, Shree K Kurup3.   

Abstract

PURPOSE: Macular pathology, including macular holes (MHs), epiretinal membranes (ERMs), and macular edema, is a cause of irreversible vision loss in the setting of uveitis. Medical management involves corticosteroids, immunomodulatory medications, and biologics to control inflammation. Pars plana vitrectomy (PPV) has been suggested as a therapy for uveitis, with reports of reduced inflammation and decreased dependence on medication postoperatively. Currently, PPV is reserved for retinal detachments, vitreous opacities, and ERMs, causing vitreomacular traction. However, little is known about the visual outcomes of PPV with ERM peel for MH, or in ERM without evidence of traction in the context of uveitis.
METHODS: Review of small case series and case reports support both conservative medical treatment and vitrectomy, independently, and in combination, in the management of macular pathology in the setting of uveitis. RESULTS AND
CONCLUSIONS: Further studies are required to study uveitic etiologies separately with respect to visual outcomes after vitreoretinal surgery and medical management.

Entities:  

Keywords:  epiretinal membrane; macular edema; macular hole; pars plana vitrectomy; uveitis; vitreoretinal surgery

Mesh:

Year:  2017        PMID: 28112568     DOI: 10.1089/jop.2016.0142

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  8 in total

1.  Do systemic steroids increase the risk of ocular complication in uveitis patients? Focus on a Italian referral center.

Authors:  Chiara Posarelli; Rosaria Talarico; Giovanna Vella; Andrea Passani; Marta Mosca; Michele Figus
Journal:  Clin Rheumatol       Date:  2019-06-06       Impact factor: 2.980

Review 2.  [Pharmacological treatment strategies and surgical options for uveitis].

Authors:  Justus G Garweg
Journal:  Ophthalmologe       Date:  2019-10       Impact factor: 1.059

3.  Visual outcomes of primary versus secondary epiretinal membrane following vitrectomy and cataract surgery.

Authors:  J Corbin Norton; Mohamed K Soliman; Yit C Yang; Shree Kurup; Ahmed B Sallam
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-10-09       Impact factor: 3.117

4.  OUTCOMES OF PARS PLANA VITRECTOMY FOR MACULAR HOLE IN PATIENTS WITH UVEITIS.

Authors:  Natalia F Callaway; Marco A Gonzalez; Yoshihiro Yonekawa; Lisa J Faia; Efrem D Mandelcorn; Rahul N Khurana; Mohamed G A Saleh; Phoebe Lin; Lucia Sobrin; Thomas A Albini
Journal:  Retina       Date:  2018-09       Impact factor: 4.256

5.  Fluorescein Angiography Findings in Eyes With Lamellar Macular Hole and Epiretinal Membrane Foveoschisis.

Authors:  Roberto dell'Omo; Mariaelena Filippelli; Serena De Turris; Luca Cimino; David H Steel; Carlos E Pavesio; Andrea Govetto; Ismael Chehaibou; Francesco Parmeggiani; Mario R Romano; Lucia Ziccardi; Enza Pirozzi; Ciro Costagliola
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-01-04       Impact factor: 4.799

6.  Optical coherence tomography findings in toxoplasma retinochoroiditis.

Authors:  Seda Karaca Adiyeke; Neslisah Kutlu Uzakgider; Sıla Doğan; Hasan Aytogan; Buket Aras; Gamze Ture; Ekrem Talay
Journal:  Indian J Ophthalmol       Date:  2021-03       Impact factor: 1.848

7.  Sequential multimodal imaging of isolated necrotic full-thickness macular hole secondary to toxoplasma retinochoroiditis.

Authors:  Shreyas Shah; George J Manayath; Ratnesh Ranjan; Narendran Venkatapathy; Anuradha Kanakath
Journal:  Am J Ophthalmol Case Rep       Date:  2021-08-12

8.  Describing the Clinical and Laboratory Features and HLA-B Pattern of Adult-Onset Idiopathic Autoimmune Uveitis at a Tertiary Hospital in South India: A Cross-Sectional Study.

Authors:  Jyothi Visalakshy; Sandeep Surendran; Salil Ganu; Kannisha Shah; C B Mithun; Vishal Marwaha; Lalitha Biswas; Niveditha Kartha; Gopal Pillai
Journal:  ScientificWorldJournal       Date:  2022-02-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.